• Sidra Shaukat Department of Physiology, Fazaia Medical College, Islamabad, Pakistan
  • Amina Nadeem Department of Physiology, Army Medical College, Rawalpindi, Pakistan
  • Fauzia Mazloom, Syeda Department of Physiology, Army Medical College, Rawalpindi, Pakistan
  • Rubab Rameez Department of Physiology, Riphah Medical and Dental College, Rawalpindi, Pakistan
  • Sadia Shaukat Department of Surgery, CMH Kharian, Kharian Cantt, Pakistan
Keywords: Heart failure, Galectin-3, Echocardiogram, Echocardiography, Ejection fraction


Background: High Galectin-3 levels are indicative of severity of heart diseases and are associated with increased risk of major adverse cardiovascular events including heart failure. The objective of this study was to determine correlation between ejection fraction and serum Galectin-3 levels recorded by simple and quick test. Methods: This cross-sectional analytical study was conducted at the Armed Forces Institute of Cardiology (AFIC) Rawalpindi. Thirty (30) healthy adults and 60 heart failure patients were selected through randomised sampling. Diagnosed cases were classified using modified NYHA classification. Group 1 included healthy adults, Group 2 included 30 mild heart failure subjects of NYHA class I and II, Group 3 included 30 severe heart failure subjects of NYHA class III and IV. Ejection fraction was recorded at AFIC with trans-thoracic echocardiography in supine and left lateral positions. Blood samples of the participants were used for estimation of Galectin-3 by ELISA using human serum Galectin-3 ELISA kit Catalogue No.  E1951Hu (Bio Assay technology). Observations were recorded on proforma, Pearson’s correlation test and ANOVA were performed using SPSS-24. Results: The LVEF was 70.7±2.78% in Group-1, 59.3±3.4% in Group-2, and 38.96±12.27% in Group-3. The LVEF showed a substantial negative correlation with serum Galectin-3 levels (r= -0.630, p<0.001). Conclusion: There is a significant negative correlation between Serum Galectin-3 and extent of functional changes of left ventricle recorded by Ejection fraction on echocardiography.

Pak J Physiol 2022;18(2):28–30


Oppedisano F, Mollace R, Tavernese A, Gliozzi M, Musolino V, Macrì R, et al. PUFA supplementation and heart failure: effects on fibrosis and cardiac remodeling. Nutrients 2021;13(9):2965.

Amin HZ, Amin LZ, Wijaya IP. Galectin-3: a novel biomarker for the prognosis of heart failure. Clujul Med 2017;90(2):129–32.

Romero A, Gabius HJ. Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target? Expert Opin Ther Targets 2019;23(10):819–28.

Barman SA, Li X, Haigh S, Kondrikov D, Mahboubi K, Bordan Z, et al. Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis. Am J Physiol Lung Cell Mol Physiol 2019;316(5):L784–97.

Špinarová M, Meluzin J, Podroužková H, Štěpánová R, Špinarová L. New echocardiographic parameters in the diagnosis of heart failure with preserved ejection fraction. Int J Cardiovasc Imaging 2018;34(2):229–35.

Devereux RB, de Simone G, Arnett DK, Best LG, Boerwinkle E, Howard BV, et al. Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. Am J Cardiol 2012;110(8):1189–94.

Pulignano G, Del Sindaco D, Jaarsma T, Stromberg A, Martensson A, Dracup K, et al. 264 Translation and validation of the Italian version of the European heart failure self‐care behaviour scale. Eur J Heart Fail Suppl 2004;3(1):64.

Mosleh W, Chaudhari MR, Sonkawade S, Mahajan S, Khalil C, Frodey K, et al. The therapeutic potential of blocking galectin-3 expression in acute myocardial infarction and mitigating inflammation of infarct region: a clinical outcome-based translational study. Biomark Insights 2018;13:1–10. DOI: 10.1177.1177271918771969.

Kanukurti J, Mohammed N, Sreedevi N, Khan SA, Baba KS, Bhaskar MV, et al. Evaluation of galectin-3 as a novel diagnostic biomarker in patients with heart failure with preserved ejection fraction. J Lab Physicians 2020;12(2):126–32.

Yin QS, Shi B, Dong L, Bi L. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol 2014;11(1):79–82.

Fernando ML, Krithika B, Silambanan S. Galectin-3: A novel biomarker of left ventricular remodelling in chronic heart failure. J. Evid. Based Med. Healthc 2020;7(16):816–22.

Shah RV, Chen‐Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010;12(8):826–32.

Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108(3):385–90.

McEvoy JW, Chen Y, Halushka MK, Christenson E, Ballantyne CM, Blumenthal RS, et al. Galectin‐3 and risk of heart failure and death in blacks and whites. J Am Heart Assoc 2016;5(5):e003079.


Download data is not yet available.
How to Cite
Shaukat S, Nadeem A, Mazloom F, Rameez R, Shaukat S. CORRELATION OF SERUM GALECTIN-3 LEVELS WITH EJECTION FRACTIONS IN HEALTHY SUBJECTS AND HEART FAILURE PATIENTS. PJP [Internet]. 30Jun.2022 [cited 26Nov.2022];18(2):28-0. Available from: